This promotional information is intended for healthcare professionals based
in the UK.
If you are not a healthcare professional in the UK, click here.
For Prescribing and Adverse Event reporting information, click here.

ELIQUIS® (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of venous thromboembolic events (VTE) in patients who have undergone elective hip or knee replacement surgery.


Explore ELIQUIS® for your
patients with DVT / PE

AMPLIFY Clinical Trial

ELIQUIS demonstrated comparable efficacy with a significant reduction in the risk of major bleeding vs. enoxaparin / warfarin in the treatment of DVT / PE1

AMPLIFY-EXT Clinical Trial

ELIQUIS 2.5 mg BD demonstrated superior efficacy vs. placebo, with no statistically significant increase in the rates of both major and major / CRNM bleeding vs. placebo in patients receiving extended treatment for the prevention of recurrent DVT / PE2

CARAVAGGIO Clinical Trial

The CARAVAGGIO clinical trial investigated the efficacy and safety of ELIQUIS vs. dalteparin for the treatment of VTE in patients with cancer3

Treatment Guidelines

ELIQUIS is recommended by NICE as a treatment option for confirmed proximal DVT or PE3

Real-World Data

In AMPLIFY, ELIQUIS demonstrated comparable efficacy with a superior major bleeding profile vs. enoxaparin / warfarin; this is complemented by RWD1,4

FOOTNOTES

BD = Twice Daily   CRNM = Clinically Relevant Non-Major   DVT = Deep Vein Thrombosis   NICE = National Institute for Health and Care Excellence   
PE = Pulmonary Embolism   RWD = Real-World Data

REFERENCES

  1. Agnelli G et al. N Engl J Med 2013; 369: 799–808.
  2. Agnelli G et al. N Engl J Med 2013; 368: 699–708.
  3. Agnelli G et al. N Engl J Med 2020; 382: 1599–1607.
  4. NICE Guideline NG158. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. March 2020.
  5. Weycker D et al. Thromb Haemost 2018; 118: 1951–1961.